Paclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial
- PMID: 22203773
- DOI: 10.1200/JCO.2011.40.2305
Paclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial
Comment on
-
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.J Clin Oncol. 2011 Nov 10;29(32):4286-93. doi: 10.1200/JCO.2010.34.1255. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990397 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
